Perspective of PMO in Compliance of Madurese Ethnic Tuberculosis Patient in Tapal Kuda Regions

Abstract

Tuberculosis cases in Indonesia are ranked at the top 10 in the world, in which East Java Province is at the 2nd highest tuberculosis cases from 33 provinces in Indonesia. In East Java, the problem of severe tuberculosis occurs in such Tapal Kuda regions as Jember, Bondowoso and Lumajang. The Case Notification Rate in each of these areas is 137 / 100.000, 65 / 100.000 population and 74 / 100.000 population respectively. The strategy to ensure patient recovery is the use of short-term antiTB

drug alloys and the application of drug control called the Direct Observed Treatment Short Course (DOTS). In the treatment of tuberculosis there is very possible the occurrence of drop out treatment or drop out. Cases of drop out have a higher risk of tuberculosis recurrence, anti-tuberculosis drug resistance, and can transmit the infection to others. Based on the data from the World Health Organization (WHO) in 2013, the resistance of tuberculosis germs resulted from non-adherence treatment of 12.6%. The Drug Controller (PMO) plays an important role in reminding, monitoring, and motivating TB patients to remain obedient to treatment. This study aims to determine the perspective of PMO in compliance to treatment of Madurese ethnic tuberculosis patients in Tapal Kuda regions. The method used is triangulation and verification using qualitative approach. The results of the study showed that according to the PMO the factors that influenced the treatment of Tuberculosis patients during the treatment period were the lack of medical expenses, the low of patient's confidence in the treatment, the lack of access to health service, and the lack of motivation of the patient to make good treatment and therefore there needs to be proactive support from PMO and family as well as ongoing comprehensive and proactive socialization related to the awareness raising of the patient about the importance of tuberculosis treatment and the improvement of patient understanding related to TB treatment.